CRISPR Therapeutics shares are trading higher after Citigroup maintained a Neutral rating on the stock and raised its price target from $55 to $70.
Portfolio Pulse from Benzinga Newsdesk
CRISPR Therapeutics shares are trading higher after Citigroup maintained a Neutral rating on the stock and raised its price target from $55 to $70.
May 23, 2023 | 3:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup maintained a Neutral rating on CRISPR Therapeutics and raised its price target from $55 to $70, leading to higher trading of CRSP shares.
Citigroup's decision to maintain a Neutral rating on CRISPR Therapeutics and raise its price target from $55 to $70 indicates a positive outlook for the company. This news has led to higher trading of CRSP shares, suggesting a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100